Business
Travere, CSL gets standard EU approval for kidney disorder treatment (TVTX:NASDAQ)
Mohammed Haneefa Nizamudeen/iStock via Getty Images
- Travere Therapeutics (NASDAQ:TVTX) and CSL Vifor (OTCQX:CMXHF) said that the European Commission has converted the conditional marketing approval into a standard marketing authorization for Filspari to treat IgA nephropathy, a kidney disorder.
- The decision follows the Committee for Medicinal Products
https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1346354281/image_1346354281.jpg?io=getty-c-w750
2025-04-29 10:07:37
